(Reuters) -Pfizer Inc on Tuesday fell short of Wall Street estimates for quarterly revenue, hit by declining sales of its COVID-19 products.
The U.S. drugmaker has said it expects 2023 to be a low point for COVID product sales following strong demand at the peak of the pandemic before a potential return to growth in 2024.
Quarterly sales from its vaccine Comirnaty and antiviral treatment Paxlovid were a combined $1.6 billion.
Analysts had expected sales of $1.40 billion for the vaccine and $1.08 billion for Paxlovid.Total revenue for the second quarter at $12.73 billion missed analysts’ estimates of $13.27 billion, according to Refinitiv data.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Sriraj Kalluvila)
